Clinical trials: Pancreatic Cancer, Advanced or Metastatic

Pancreatic Neuroendocrine Tumors

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

• Completed
• Age: 18 to 100 years
• Phase 4
• Results posted

To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.

Trial name

NCT02842749

Testing

everolimus

Where

5 sites in China

Volunteers

61 people

Sponsor

Novartis Pharmaceuticals